Literature DB >> 19481176

Aminophylline increases ventilation and diaphragm contractility in awake canines.

J V Jagers1, H G Hawes, P A Easton.   

Abstract

Traditional theophylline bronchodilators are still used clinically, especially in COPD. However, the effect of theophyllines on ventilation and respiratory muscles remains uncertain and these effects have not been measured directly in any awake, intact mammal. We hypothesized that aminophylline in the usual therapeutic dosage range, would elicit in the awake mammal, a significant increase in ventilation, and a significant increase in costal diaphragm shortening and contractility as recorded directly from the muscle. Therefore, we studied 13 awake canines, which had been chronically implanted with fine-wire EMG electrodes and sonomicrometer crystals in the costal segment of the diaphragm. Ventilatory parameters, moving average muscle EMG activity and muscle length and shortening, were measured at baseline and with aminophylline, during resting and hypercapnic stimulated breathing. Experiments were carried out prior to administration of aminophylline (baseline), and 1.5h after loading and ongoing infusion with aminophylline. Minute ventilation, tidal volume and respiratory frequency all increased significantly with aminophylline, both during resting breathing and at equivalent levels of hypercapnic stimulated breathing. Costal diaphragm baseline muscle length was entirely unchanged with aminophylline. Costal diaphragm shortening increased significantly with aminophylline while corresponding costal diaphragm EMG activity remained constant, consistent with increased diaphragm contractility. Thus, in awake, intact mammals, aminophylline in usual therapeutic dosage elicits increased ventilation and increased contractility of respiratory muscles.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19481176     DOI: 10.1016/j.resp.2009.05.008

Source DB:  PubMed          Journal:  Respir Physiol Neurobiol        ISSN: 1569-9048            Impact factor:   1.931


  7 in total

1.  Ultrasound assessment of the diaphragm: Preliminary study of a canine model of X-linked myotubular myopathy.

Authors:  Aarti Sarwal; Michael S Cartwright; Francis O Walker; Erin Mitchell; Anna Buj-Bello; Alan H Beggs; Martin K Childers
Journal:  Muscle Nerve       Date:  2014-08-30       Impact factor: 3.217

2.  A Study of Patients with "Interface Respiratory Failure" Due to Chronic Obstructive Pulmonary Diseases.

Authors:  Y Wang; J Zhang; J Feng; J Cao; B-Y Chen
Journal:  West Indian Med J       Date:  2015-01-22       Impact factor: 0.171

3.  Effects of Theophylline with Methylprednisolone Combination Therapy on Biomechanics and Histopathology in Diaphragm Muscles of Rats.

Authors:  Nureddin Yuzkat; Ismail Kati; Yasemin Isik; Servet Kavak; Ugur Goktas; Nurettin Cengiz
Journal:  Inflammation       Date:  2016-10       Impact factor: 4.092

4.  Bufei Jianpi granules improve skeletal muscle and mitochondrial dysfunction in rats with chronic obstructive pulmonary disease.

Authors:  Yuqiong Dong; Ya Li; Yafei Sun; Jing Mao; Fengjia Yao; Yange Tian; Lili Wang; Linlin Li; Suyun Li; Jiansheng Li
Journal:  BMC Complement Altern Med       Date:  2015-03-10       Impact factor: 3.659

5.  Low dose aminophylline effectively decreases the risk of post-operative apnea in premature infants.

Authors:  Seyed Amir Mohajerani; Fatemeh Roodneshin
Journal:  Tanaffos       Date:  2014

6.  Effects of theophylline therapy on respiratory muscle strength in patients with prolonged mechanical ventilation: A retrospective cohort study.

Authors:  Teng-Jen Yu; Yu-Chih Liu; Chien-Min Chu; Han-Chung Hu; Kuo-Chin Kao
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

7.  Efficacy of dexamethasone, salbutamol, and reduced respirable particulate concentration on aerobic capacity in horses with smoke-induced mild asthma.

Authors:  Stephanie L Bond; Persephone Greco-Otto; Jacqueline MacLeod; Angelica Galezowski; Warwick Bayly; Renaud Léguillette
Journal:  J Vet Intern Med       Date:  2020-01-18       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.